GIST adjuvant therapy – some answers and more questions

Burton Eisenberg

Imatinib is known to be effective in the first-line treatment of metastatic gastrointestinal stromal tumours. A randomised, placebo-controlled trial has now shown that imatinib is safe and improves recurrence-free survival when used as adjuvant therapy after surgical resection of a primary gastrointestinal stromal tumour.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.


*


UA-77507851-1